May 16, 2021 21:28 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Delhi extends lockdown to curb Covid spread by another week | Assam CM Himanta Biswa Sarma visits Covid facility of govt hospital at late night | Congress MP Rajeev Satav dies of Covid-19 | India records 3.29 fresh Covid cases, 4,077 deaths in last 24 hours | Veteran journalist Sunil Jain passes away, PM Modi condoles
Cipla receives final approval for generic version of Shire's Firazyr

Cipla receives final approval for generic version of Shire's Firazyr

India Blooms News Service | @indiablooms | 14 Jul 2020, 04:09 pm

Mumbai/UNI:  Pharma major Cipla on Tuesday said that it has received final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA).

Cipla's Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire's Firazyr.

Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

According to IQVIA (IMS Health), Firazyr and its generic equivalents had US sales of approximately USD270M for the 12-month period ending May 2020.